AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Inclusion Criteria:

Histologically or cytologically documented invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer
Radiographically documented disease progression either on or following the last dose of the prior regimen for epithelial ovarian, primary peritoneal, or fallopian tube cancer
Subjects must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound.
Female 18 years of age or older at the time the written informed consent is obtained
Adequate organ and hematological function

Exclusion Criteria:

Subjects who have received more than 3 previous regimens of anti cancer therapy for epithelial ovarian, primary peritoneal or fallopian tube cancer
Subjects treated with prior pegylated liposomal doxorubicin (PLD) or any anthracycline-based or mitoxantrone-based chemotherapy
Subjects with primary platinum-refractory disease
Subjects with platinum-free interval (PFI) > 12 months from their last platinum based therapy
History of central nervous system metastasis
Major surgery within 28 days prior to randomization or still recovering from prior surgery